Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
NCT04958993Phase 2Terminated
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Started Nov 2020; status: terminated.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04958993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958993.